Curis, Inc. (CRIS) Cut to “Sell” at Zacks Investment Research
Zacks Investment Research cut shares of Curis, Inc. (NASDAQ:CRIS) from a hold rating to a sell rating in a research report released on Friday.
According to Zacks, “Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. Curis’ product development involves the use of small molecules or proteins to modulate these pathways. The company has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of cancer, neurological disorders, hair growth, kidney and other diseases, as well as cardiovascular disease. “
Several other equities analysts also recently weighed in on the stock. Guggenheim initiated coverage on shares of Curis in a research note on Monday, October 23rd. They issued a buy rating and a $7.00 target price for the company. ValuEngine lowered shares of Curis from a hold rating to a sell rating in a research report on Friday, September 15th. Finally, BidaskClub lowered shares of Curis from a hold rating to a sell rating in a research report on Thursday, July 27th. Three analysts have rated the stock with a sell rating and three have issued a buy rating to the company’s stock. The company currently has an average rating of Hold and a consensus price target of $6.50.
Shares of Curis (NASDAQ CRIS) opened at $1.23 on Friday. Curis has a 1-year low of $1.20 and a 1-year high of $3.72. The company has a debt-to-equity ratio of 1.24, a current ratio of 5.15 and a quick ratio of 5.15.
Curis (NASDAQ:CRIS) last posted its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.02). Curis had a negative return on equity of 250.58% and a negative net margin of 629.29%. The company had revenue of $2.44 million for the quarter, compared to analysts’ expectations of $2.19 million. During the same quarter last year, the business posted ($0.21) EPS. The business’s quarterly revenue was up 38.6% on a year-over-year basis. equities research analysts expect that Curis will post -0.41 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This article was reported by Watch List News and is the property of of Watch List News. If you are viewing this article on another publication, it was stolen and republished in violation of US and international copyright legislation. The legal version of this article can be viewed at https://www.watchlistnews.com/curis-inc-cris-cut-to-sell-at-zacks-investment-research/1699274.html.
Hedge funds have recently added to or reduced their stakes in the company. Bank of America Corp DE lifted its position in Curis by 58.7% during the first quarter. Bank of America Corp DE now owns 36,348 shares of the biotechnology company’s stock valued at $101,000 after purchasing an additional 13,448 shares during the last quarter. Prudential Financial Inc. bought a new stake in Curis during the first quarter valued at approximately $105,000. OxFORD Asset Management LLP purchased a new position in shares of Curis during the second quarter worth approximately $115,000. FNY Partners Fund LP raised its stake in shares of Curis by 350.0% during the third quarter. FNY Partners Fund LP now owns 67,500 shares of the biotechnology company’s stock worth $100,000 after acquiring an additional 52,500 shares in the last quarter. Finally, Voya Investment Management LLC raised its stake in shares of Curis by 21.8% during the second quarter. Voya Investment Management LLC now owns 68,138 shares of the biotechnology company’s stock worth $129,000 after acquiring an additional 12,207 shares in the last quarter. Institutional investors own 46.01% of the company’s stock.
Curis Company Profile
Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.